SAN DIEGO, Nov. 19, 2025 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its Managed Access Program (MAP) for investigational…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
